<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00797784</url>
  </required_header>
  <id_info>
    <org_study_id>FADC</org_study_id>
    <nct_id>NCT00797784</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus</brief_title>
  <acronym>DISCLUP2008</acronym>
  <official_title>A Phase 2 Open Label Study to Assess the Efficacy and Safety of Etanercept (Enbrel®)for the Treatment of Discoid Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Academic Dermatology Centers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Florida Academic Dermatology Centers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 20 week study to assess the safety and efficacy of etanercept(Enbrel®)for the treatment of
      Discoid Lupus Erythematosus
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients responding to study treatment using the Cutaneous Lupus Erythematous Disease Area Severity Index(CLASI)defined as a decrease of 50% form baseline.</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 20 in Dermatology Life Quality Index and Pysician's Global Assessment of disease measurements</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Discoid Lupus Erythematosus (DLE)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept(Enbrel®)</intervention_name>
    <description>etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with discoid lupus erythematosus .Subjects require to have confirmation of
             diagnosis by a skin biopsy .This can be undertaken at the screening visit if no
             previous biopsy confirmation available.

        And;

          -  Having failed steroids (topical, intralesional, systemic) and are candidates for
             antimalarial therapy

          -  Negative ANA

        Have no history of latent or active TB prior to screening.

        Exclusion Criteria:

          -  Subjects allergic to sunscreens

          -  Prior treatment with anti-TNF therapies

          -  Subjects who do not have a previous skin biopsy result confirming a DLE diagnosis and
             who are unwilling to undergo this procedure at screening.

          -  Subjects currently receiving systemic steroid therapy (or have received in the last 3
             months)

          -  Known hypersensitivity to Enbrel® (etanercept) or any of its components or known to
             have antibodies to etanercept.

          -  Prior or concurrent use of cyclophosphamide therapy

          -  Concurrent sulfasalazine therapy.

          -  Known HIV-positive status or known history of any other immuno-suppressing disease.

          -  Any mycobacterial disease or high risk factors for tuberculosis (TB), such as family
             member with TB, positive purified protein derivative (PPD) or taking anti-tuberculosis
             medication

          -  Active or chronic infection within 4 weeks before screening visit, or between the
             screening and baseline visits.

          -  Severe comorbidities (diabetes mellitus requiring insulin; CHF of any severity; or
             myocardial infarction, cerebrovascular accident or transient ischemic attack within 6
             months of screening visit; unstable angina pectoris; uncontrolled hypertension
             (sitting systolic BP &lt;80 mm Hg or &gt; 160 or diastolic BP &gt; 100 mm Hg); oxygen-dependent
             severe pulmonary disease; history of cancer within 5 years [other than resected
             cutaneous basal or squamous cell carcinoma of the skin or in situ cervical cancer])

          -  Systemic lupus erythematosus, history of multiple sclerosis, transverse myelitis,
             optic neuritis or seizure disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Annika M Grant, RN, MBA</last_name>
    <phone>305 324 2110</phone>
    <phone_ext>210</phone_ext>
    <email>annika@fadcenter.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Academic Dermatology Centers</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika M Grant, RN,MBA</last_name>
      <phone>305-324-2110</phone>
      <phone_ext>210</phone_ext>
      <email>annika@fadcenter.com</email>
    </contact>
    <investigator>
      <last_name>Francisco A Kerdel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2008</study_first_submitted>
  <study_first_submitted_qc>November 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2008</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Francisco A Kerdel,M.D.</name_title>
    <organization>Florida Academic Dermatology Centers</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Lupus Erythematosus, Discoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

